• Explore /
  • Poster
  • / A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection.

A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection.

Abstract Poster

Authors

null

Neil Gildener-Leapman

University of Pittsburgh Medical Center, Pittsburgh, PA

Neil Gildener-Leapman , Robert L. Ferris , James Ohr , Athanassios Argiris , John J. Nemunaitis , Neil N. Senzer , Cindi Bedell , Neil D. Gross , John T. Vetto , Maki Tanaka , Yukihiro Nishiyama , Richard S. Ungerleider

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Viral Therapy

Clinical Trial Registration Number

NCT01017185

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3099)

DOI

10.1200/jco.2013.31.15_suppl.3099

Abstract #

3099

Poster Bd #

21B

Abstract Disclosures

Similar Posters

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers.

Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers.

First Author: Nandita Bose

First Author: Chunjie Li

First Author: Candace Bavette Mainor

First Author: Raffit Hassan